Ebik, BeratAygan, MustafaTuncel, Elif TugbaKacmaz, HuseyinEkin, NazimArpa, MedeniYalcin, Kendal2024-04-242024-04-2420221307-58882757-7392https://doi.org/10.14744/hf.2022.2022.0016https://search.trdizin.gov.tr/yayin/detay/1173909https://hdl.handle.net/11468/18491Background and Aim: Several studies have suggested that treatment with direct-acting antivirals (DAAs) in patients with chronic hepatitis C virus (HCV) may be associated with an increased risk of developing hepatocellular carcinoma (HCC). We investigated the incidence and risk factors of HCC in HCV patients who achieved a sustained virologic response (SVR) following DAA therapies. Materials and Methods: The medical data of patients who were diagnosed with HCV and received DAA therapy in two tertiary centers in Turkey were retrospectively collected. Results: Among them, 75 patients (52.4%) were noncirrhotic and 68 patients (47.6%) were cirrhotic. The overall SVR rate was 97.2% (139/143). It was 100% in noncirrhotic and 94.1% in cirrhotic patients. HCC was developed in 5 (7.4%) patients, all of whom had baseline cirrhosis. The annual rate of HCC occurrence was 2.94%, and the 5-year cumulative incidence of HCC was 7.3%. The mean Child-Pugh score (CPS) and Model for End-Stage Liver Disease (MELD) score significantly decreased after DAA treatment (CPS 7.0 vs 5.9, p=0.001; MELD 10.8 vs 9.5, =-0.003). Conclusion: There was no significant increase in the rate of HCC in cirrhotic HCV patients treated with DAAs. This treatment led to a remarkably high SVR rate and lowered CPS and MELD scores in cirrhotic HCV patients.eninfo:eu-repo/semantics/openAccessChronic Hepatitis C InfectionDirect-Acting Antiviral AgentsHepatocellular CarcinomaArticle338287WOS:00086355640000311739093617709910.14744/hf.2022.2022.0016N/A